AlphAIAlphAI — Financial news for AI agents
tradingview.com

BTIG maintains Buy rating on CryoPort, $26 price target

BTIG maintained a Buy rating on CryoPort with a $26 price target, implying 54.4% upside from the Oct 12 close. The firm cites strong revenue growth prospects due to the expanding cell and gene therapy market and CryoPort's leadership in cold-chain logistics.

Original reporting
tradingview.com
Published Oct 13, 2026, 10:13 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 13, 2026, 10:32 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
BTIG maintains Buy rating on CryoPort, $26 price target — source image
Source · tradingview.com
Decision brief

The 30-second read

Med
01

Why it matters

The new $26 target suggests a significant upside, which could drive short‑term buying pressure.

02

Market read

Analyst upgrade with a higher price target may influence CryoPort's stock movement.

03

What to watch

Potential regulatory or reimbursement challenges for cell and gene therapy logistics.

Relevance 6/10Novelty 6/10Timing: today

Background

Analyst note from BTIG covering CryoPort's growth prospects in the expanding cell and gene therapy market.

Market effects

Sector

Positive outlook for life‑sciences logistics and cold‑chain providers.

Regional

Limited to U.S. biotech and logistics investors.

Global

Modest, as CryoPort is a niche player.

Counterpoint

What could challenge this read

The target may be overly optimistic given execution risks in scaling cold‑chain services.

Key entities

  • Company
    CryoPort

    Cold‑chain logistics provider for life‑sciences.

  • Analyst
    BTIG

    Equity research firm issuing the rating and target.

Read at source← All news

Related articles

$CYRXMed

CryoPort Q3 Earnings Call Highlights

CryoPort reported Q3 supporting 23 commercial therapies and 788 clinical trials. China operations contribute 3-4% of revenue. The company expects five regulatory filings and two potential new therapy approvals in 2026. Guidance is conservative, focusing on existing clients. Expansion plans include new BioServices capabilities in Paris and California, with long-term margin goals of 55% gross and 30% adjusted EBITDA.

finance.yahoo.com
$CYRXMed

Cryoport Reports Third Quarter 2026 Financial Results

Cryoport, Inc. (CYRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Cryoport Reports Third Quarter 2026 Financial Results · Third quarter revenue grew 14% year-over-year to $50.2 million · Commercial Cell and Gene Therapy revenue increased 20% year-over-year · Supporting a record 788 global clinical trials and 23 commercially approve

SEC EDGAR 8-K
$CYRXMedAI 8/10

Cryoport (CYRX) Q2 2026 Earnings Call Transcript

Cryoport (CYRX) reported Q2 2026 revenue of $49 million, up from prior periods, led by Life Science Services. Life Science Services revenue rose 15% year over year, with biostorage and bioservices up 25%. Support for commercial cell and gene therapy rose 9% to $9.4 million. Adjusted EBITDA turned positive at $0.4 million. Full-year 2026 revenue guidance remains $192 million to $196 million.

yahoo.com
$CYRXMed

Cryoport Reports Second Quarter 2026 Financial Results

Cryoport, Inc. (CYRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Cryoport Reports Second Quarter 2026 Financial Results · Second quarter revenue grew 8% year-over-year to $49.0 million · Life Sciences Services revenue increased 15% year-over-year · BioStorage/BioServices revenue grew 25% year-over-year · Supporting 779 global clin

SEC EDGAR 8-K
$IRENMed

IREN Says New AI Cloud Customers Are Prepaying 90% of the Chips

IREN (NASDAQ:IREN) announced a five-year AI Cloud contract with 90% prepayment on GPU capex, generating $22M annualized revenue per megawatt. Stock fell 16.95% to $18.03 but rose 10.65% after hours. Revenue rose 66% to $228M, with AI Cloud revenue at $200M. Cash decreased to $3.52B, net debt increased to $4.43B. IREN targets 90% GPU financing through prepayments.

247wallst.com
$CATXMedAI 9/10

Perspective Therapeutics Presents Promising [212Pb]Lapemelanotide Zapixetar (VMT01) Monotherapy Data from a Phase 1/2a Study in Heavily Pretreated Advanced…

Perspective Therapeutics, Inc. (CATX) filed an SEC Form 8-K — Other Events. Perspective Therapeutics Presents Promising [212Pb]Lapemelanotide Zapixetar (VMT01) Monotherapy Data from a Phase 1/2a Study in Heavily Pretreated Advanced Melanoma Patients at SITC 2026 • Meaningful antitumor activity observed at the 3.0 mCi monotherapy dose with 75% disease con

SEC EDGAR 8-K